Cardiac Transplantation: Any Role Left?

Heart Failure Clinics

Volumn 3, Issue 3, 2007, Pages 321-347

  Cadeiras, Martin ^a   von Bayern, Manuel Prinz ^a   Deng, Mario C ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPRENOLOL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; ENOXIMONE; EPLERENONE; IBOPAMINE; INOTROPIC AGENT; LEVOSIMENDAN; METOPROLOL; METOPROLOL TARTRATE; MILRINONE; PIPERANOMETOZINE; PLACEBO; PRACTOLOL; PROSTACYCLIN; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; XAMOTEROL;

AORTA VALVE; ASSISTED CIRCULATION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG DOSE TITRATION; ELECTROPHYSIOLOGY; HEALTH CARE COST; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SURGERY; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; MITRAL VALVE; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; QRS COMPLEX; REVIEW; SURVIVAL; TACHYCARDIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; ELECTRIC COUNTERSHOCK; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS;

EID: 34548161665     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2007.04.004     Document Type: Review

References (139)

1. Hunt S.A., Rider A.K., Stinson E.B., et al. Does cardiac transplantation prolong life and improve its quality? An updated report. Circulation 54 6 Suppl (1976) III56-III60
2. th Bethesda conference: cardiac transplantation. Task force 3: recipient guidelines/prioritization. J Am Coll Cardiol 22 1 (1993) 21-23
3. Taylor D.O., Edwards L.B., Boucek M.M., et al. International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 (2006) 869-879
4. Mancini D.M., Eisen H., Kussmaul W., et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83 (1991) 778-786
5. Aaronson K.D., Schwartz J.S., Chen T.M., et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 (1997) 2660-2667
6. Deng M.C., De Meester J.M., Smits J.M., et al. Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative outcome and clinical profiles in transplantation (COCPIT) study group. BMJ 321 (2000) 540-545
7. Deng M.C., Edwards L.B., Hertz M.I., et al. International Society for Heart and Lung Transplantation. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report-2005. J Heart Lung Transplant 24 (2005) 1182-1187
8. Butler J., Khadim G., Paul K.M., et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 43 5 (2004) 787-793
9. Freudenberger R.S., Kim J., Tawfik I., et al. Optimal medical therapy is superior to transplantation for the treatment of class I, II, and III heart failure: a decision analytic approach. Circulation 114 1 Suppl (2006) I62-I66
10. Jimenez J., Bennett Edwards L., Higgins R., et al. Should stable UNOS status 2 patients be transplanted?. J Heart Lung Transplant 24 (2005) 178-183
11. Rose E.A., Gelijns A.C., Moskowitz A.J., et al., Randomized evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
12. Swedberg K., and Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
13. Swedberg K., Kjekshus J., and Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 20 2 (1999) 136-139
14. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 5 (1991) 303-310
15. SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med 325 5 (1991) 293-302
16. AIRE investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Lancet 342 8875 (1993) 821-828
17. Waagstein F., Hjalmarson A., Varnauskas E., et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37 10 (1975) 1022-1036
18. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 21 (1996) 1349-1355
19. CIBIS-II investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 353 9146 (1999) 9-13
20. MERIT investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 9169 (1999) 2001-2007
21. Packer M., Coats A.J., Fowler M.B., et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 22 (2001) 1651-1658
22. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 362 9377 (2003) 7-13
23. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341 (1999) 709-717
24. Pitt B., Remme W., Zannad F., et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
25. Pitt B., Gheorghiade M., Zannad F., et al., On behalf of the EPHESUS Investigators. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
26. Cohn J.N., Tognoni G., and for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin- receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
27. Granger C.B., McMurray J.J., Yusuf S., et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362 9386 (2003) 772-776
28. McMurray J.J., Ostergren J., Swedberg K., et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 362 9386 (2003) 767-771
29. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone trial investigators. N Engl J Med 339 (1998) 1810-1816
30. Feldman A.M., Bristow M.R., Parmley W.W., et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone study group. N Engl J Med 329 (1993) 149-155
31. Ryden L., and for the Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. The Xamoterol in severe heart failure study group. Lancet 336 (1990) 1-6
32. Hampton J.R., van Veldhuisen D.J., Kleber F.X., et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) investigators. Lancet 349 (1997) 971-977
33. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med 325 (1991) 1468-1475
34. Packer M., Caspi A., Charlon V., et al. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure: results of the REACH-1 trial. Circulation 98 Suppl I (1998) I-3. [abstract]
35. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
36. Brozena S.C., Twomey C., Goldberg L.R., et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant 23 9 (2004) 1082-1086
37. Upadya S., Lee F.A., Saldarriaga C., et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant 23 4 (2004) 466-472
38. Lowes B.D., Higginbotham M., Petrovich L., et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone study group. J Am Coll Cardiol 36 2 (2000) 501-508
39. Metra M. European Society of Cardiology Congress 2005. Stockholm (Sweden). September 4-7, 2005.
40. Hunt S.A. American college of cardiology; American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 6 (2005) e1-e82
41. Gheorghiade M., De Luca L., and Bonow R.O. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am J Cardiol 96 12A (2005) 3L-9L
42. Cazeau S., Leclercq C., Lavergne T., et al. Multisite Stimulation in Cardiomyopathies (MUSTIC) study investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 (2001) 873-880
43. Abraham W.T., Fisher W.G., Smith A.L., et al., MIRACLE Study Group. Multicenter cardiac resynchronization in chronic heart failure. N Engl J Med 346 24 (2002) 1845-1853
44. Bristow M.R., Saxon L.A., Boehmer J., et al. Comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 21 (2004) 2140-2150
45. Cleland J.G., Coletta A.P., Lammiman M., et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail 7 6 (2005) 1070-1075
46. Cleland J.G., Daubert J.C., Erdmann E., et al. Cardiac Resynchronization-Heart Failure (CARE-HF) study investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 15 (2005) 1539-1549
47. Bardy G.H., Lee K.L., Mark D.B., et al. Sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
48. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 (1996) 1933-1940
49. Moss A.J., Zareba W., Hall W.J., et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
50. BARI investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The bypass angioplasty revascularization investigation (BARI) investigators. N Engl J Med 335 (1996) 217-225
51. Morrison D.A., Sethi G., Sacks J., et al. Angina with extremely serious operative mortality evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol 38 1 (2001) 143-149
52. Hannan E.L., Racz M.J., Walford G., et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 352 (2005) 2174-2183
53. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
54. Joyce D., Loebe M., Noon G.P., et al. Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Curr Opin Cardiol 6 (2003) 454-457
55. STICH Trial. Available at: https://www.stichtrial.org/. Accessed November, 2006.
56. Veenhuyzen G.D., Singh S.N., McAreavey D., et al. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation 104 (2001) 1489-1493
57. Kron I.L., Flanagan T.L., Blackbourne L.H., et al. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg 210 (1989) 348-354
58. Winkel E., and Piccione W. Coronary artery bypass surgery in patients with left ventricular dysfunction: Candidate selection and perioperative care. J Heart Lung Transplant 16 (1997) S19-S24
59. Di Carli M.F., Asgarzadie F., Schelbert H.R., et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 92 (1995) 3436-3444
60. Elefteriades J.A., Tolis G., Levi E., et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival and improved EF and functional state. J Am Coll Cardiol 22 (1993) 1411-1417
61. Hausmann H., Topp H., Siniawski H., et al. Decision-making in end-stage coronary artery disease: revascularization or heart transplantation?. Ann Thorac Surg 64 (1997) 1296-1302
62. Mickleborough L.L., Maruyama H., Takagi Y., et al. Results of revascularization in patients with severe left ventricular dysfunction. Circulation 92 Suppl II (1995) S73-S79
63. Olson P.S., Kassis E., and Niebuhr-Jorgensen U. Coronary artery bypass surgery in patients with severe left ventricular dysfunction. Thorac Cardiovasc Surg 41 (1993) 118-120
64. Oz M.C., Gelijns A.C., Miller L., et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann Surg 238 4 (2003) 577-583
65. Dreyfus G., Duboc D., Blasco A., et al. Coronary surgery can be an alternative to heart transplantation in selected patients with end-stage ischemic heart disease. Eur J Cardiothorac Surg 7 (1993) 482-488
66. Lansman S.L., Cohen M., Galla J.D., et al. Coronary bypass with ejection fraction of 0.20 or less using centigrade cardioplegia: longterm follow-up. Ann Thorac Surg 56 (1993) 480-486
67. Tjan T.D.T., Kondruweit M., Scheld H.H., et al. The bad ventricle-revascularization versus transplantation. Thorac Cardiovasc Surg 48 (2000) 1-6
68. Bolling S.F., Pagani F.D., Deeb G.M., et al. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. Thorac Cardiovasc Surg 115 (1998) 381-386
69. Wu A.H., Aaronson K.D., Bolling S.F., et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45 (2005) 381-387
70. Acker M.A., Bolling S., Shemin R., et al. Acorn mitral valve surgery in heart failure: insights from the acorn clinical trial. J Thorac Cardiovasc Surg 132 (2006) 568-577
71. Bonow R.O., Carabellow B.A., Chatterjee K., et al. ACC/AHA 2006 Practice guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of cardiology/american heart association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease)...
72. Connolly H.M., Oh J.K., Schaff H.V., et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: result of aortic valve replacement in 52 patients. Circulation 101 (2000) 1940-1946
73. Pereira J.J., Lauer M.S., Bashir M., et al. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol 39 8 (2002) 1356-1363
74. Chukwuemeka A., Rao V., Armstrong S., et al. Aortic valve replacement: a safe and durable option in patients with impaired left ventricular systolic function. Eur J Cardiothorac Surg 29 (2006) 133-138
75. Athanasuleas C.L., Stanley Jr. A.W., Buckberg G.D., et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol 37 (2001) 1199-1209
76. Athanasuleas C.L., Buckberg G.D., Stanley A.W., et al., RESTORE group. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol 44 (2004) 1439-1445
77. Stevenson L.W. Left ventricular assist devices as destination therapy for end-stage heart failure. Curr Treat Options Cardiovasc Med 6 (2004) 471-479
78. Young J.B., Rogers J.G., Portner P.M., et al. Bridge to eligibility: LVAS-support in patients with relative contraindications to transplantation. J Heart Lung Transplant 24 (2005) S75
79. Jurmann M.J., Weng Y., Drews T., et al. Permanent mechanical circulatory support in patients of advanced age. Eur J Cardiothorac Surg 25 (2004) 610-618
80. Siegenthaler M.P., Westaby S., Frazier O.H., et al. Advanced heart failure: study feasibility of long term continuous axial flow pump support. Eur Heart J 26 (2005) 1031-1038
81. Holman W.L., Park S.J., Long J.W., et al. Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant 23 (2004) 1359-1365
82. Hood L., Heath J.R., Phelps M.E., et al. Systems biology and new technologies enable predictive and preventative medicine. Science 306 (2004) 640-643
83. Simon D., Fischer S., Grossman A., et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 40 (2005) 1108-1115
84. Lazar R.M., Shapiro P.A., Jaski B.E., et al. Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation 109 (2004) 2423-2427
85. Martin J., Siegenthaler M.P., Friesewinkel O., et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation: a preliminary study. Eur J Cardiothorac Surg 25 (2004) 971-977
86. Salzberg S.P., Lachat M.L., von Harbou K., et al. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg 27 (2005) 222-225
87. Dowling R.D., Park S.J., Pagani F.D., et al. HeartMate VE LVAS design enhancements and its impact on device reliability. Eur J Cardiothorac Surg 25 (2004) 958-963
88. Birks E.J., Tansley P.D., Yacoub M.H., et al. Incidence and clinical management of life-threatening left ventricular assist device failure. J Heart Lung Transplant 23 (2004) 964-969
89. Mehra M.R., Kobashigawa J., Starling R., et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant 25 9 (2006) 1024-1042
90. Deng M.C., Smits J.M., and Packer M. Selecting patients for heart transplantation: which patients are too well for transplant?. Curr Opin Cardiol 17 2 (2002) 137-144
91. Zugck C., Haunstetter A., Kruger C., et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 39 10 (2002) 1615-1622
92. Lund L.H., Aaronson K.D., and Mancini D.M. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol 92 11 (2003) 1350-1354
93. O'Neill J.O., Young J.B., Pothier C.E., et al. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 111 18 (2005) 2313-2318
94. McAlister F.A., Stewart S., Ferrua S., et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 44 4 (2004) 810-819
95. Koelling T.M., Johnson M.L., Cody R.J., et al. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 111 (2005) 179-185
96. Inglis S.C., Pearson S., Treen S., et al. Extending the horizon in chronic heart failure. Effects of multidisciplinary, home-based intervention relative to usual care. Circulation 114 23 (2006) 2466-2473
97. International HapMap Consortium. A haplotype map of the human genome. Nature 437 (2005) 1299-1320
98. Packer M., Abraham W.T., Mehra M.R., et al. Prospective Evaluation and Identification of Cardiac Decompensation by ICG Test (PREDICT) study investigators and coordinators. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. J Am Coll Cardiol 47 11 (2006) 2245-2252
99. Bourge R.C. Case Studies in advanced monitoring with the Chronicle device. Rev Cardiovasc Med 7 Suppl 1 (2006) S56-S61
100. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 8 (2002) 920-926
101. Swedberg K., Bristow M.R., Cohn J.N., et al., Moxonidine Safety and Efficacy (MOXSE) Investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105 15 (2002) 1797-1803
102. Bozkurt B., Torre-Amione G., Warren M.S., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103 8 (2001) 1044-1047
103. Rich S., and McLaughlin V.V. Endothelian receptor blockers in cardiovascular disease. Circulation 108 18 (2003) 2184-2190
104. O'Connor C.M., Gattis W.A., Adams Jr. K.F., et al. Randomized Intravenous TeZosentan Study-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study-4 (RITZ-4). J Am Coll Cardiol 41 9 (2003) 1452-1457
105. Kaluski E., Kobrin I., Zimlickman R., et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41 2 (2003) 204-210
106. Teerlink J.R., McMurray J.J., Bourge R.C., et al., VERITAS Investigators. Tezosentan in patients with acute heart failure: design of the Value on Endothelin Receptor Inhibitor with Tezosentan in Acute Heart Failure Study (VERITAS). Am Heart J 150 1 (2005) 46-53
107. Anand I., McMurray J.J., Cohn J.N., et al., EARTH Investigators. Long-terms effects of darusentan on left ventricular remodeling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 364 9431 (2004) 347-354
108. Lauscher T.F., Enseleit F., Pacher R., et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106 21 (2002) 2666-2672
109. Deswal A., Bozkurt B., Seta Y., et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99 25 (1999) 3224-3226
110. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 13 (2004) 1594-1602
111. Chung E.S., Packer M., Lo K.H., et al. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 25 (2003) 3133-3140
112. Zohlnhöfer D., Ott I., Mehilli J., et al. REVIVAL-2 Investigators. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295 9 (2006) 1003-1010
113. Wollert K.C., Meyer G.P., Lotz J., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364 9429 (2004) 141-148
114. Strauer B.E., Brehm M., Zeus T., et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 46 9 (2005) 1651-1658
115. Schachinger V., Erbs S., Elsasser A., et al. REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355 12 (2006) 1210-1221
116. Assmus B., Honold J., Schachinger V., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355 12 (2006) 1222-1232
117. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
118. Caron P.R., Mullican M.D., Mashal R.D., et al. Chemogenomic approaches to drug discovery. Curr Opin Chem Biol 5 4 (2001) 464-470
119. Di Bernardo D., Thompson M.J., Gardner T.S., et al. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat Biotechnol 23 3 (2005) 377-378
120. Gardner T.S., di Bernardo D., Lorenz D., et al. Inferring genetic networks and identifying compound mode of action via expression profiling. Science 301 5629 (2003) 102-105
121. Cadeiras M., Von Bayern M.P., Pal A., et al. Destination therapy: an alternative for end-stage heart failure patients not eligible for heart transplantation. Curr Opin Organ Transplant 10 (2005) 369-375
122. Stevenson L.W. The evolving role of mechanical circulatory support in advanced heart failure. In: Frazier O.H., and Kirklin J.K. (Eds). Mechanical circulatory support (ISHLT Monograph Series Volume 1) (2006), Elsevier, Philadelphia
123. Deng M.C., and Naka Y. Mechanical circulatory support therapy in advanced heart failure (2006), World Scientific Press
124. Deng M.C., Eisen H.J., Mehra M.R., et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 6 1 (2006) 150-160
125. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355 (2006) 1873-1884
126. Miller L.W., Nelson K.E., Bostic R.R., et al. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant 25 7 (2006) 778-784
127. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 45 9 (2005) 1532-1537
128. Marboe C.C., Billingham M., Eisen H., et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 24 7 Suppl (2005) S219-S226
129. Starling R.C., Pham M., Valantine H., et al. Working Group on Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant 25 2 (2006) 1389-1395
130. National Institutes of Health. IMAGE: a comparison of allomap molecular testing and traditional biopsy-based surveillance for heart transplant rejection. ClincalTrials.gov NCT00351559. Available at: http://clinicaltrials.gov/ct/show/NCT00351559. Accessed July 24, 2007.
131. Stevenson L.W., Miller L.W., Desvigne-Nickens P., et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 110 (2004) 975-981
132. Hunt S.A. A fair way of donating hearts for transplantation. BMJ 321 (2000) 526-526
133. Gibbons R.D., Meltzer D., Duan N., et al. Institute of medicine committee on organ procurement and transplantation, waiting for organ transplantation. Science 287 (2000) 237-238
134. Goldberg L.R., and Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 113 24 (2006) 2851-2860
135. Meltzer D. Waiting for organ transplantation. Transplant Proc 35 3 (2003) 969-970
136. Chang G.J., Mahanty H.D., Ascher N.L., et al. Expanding the donor pool: can the Spanish model work in the United States?. Am J Transplant 3 10 (2003) 1259-1263
137. Gundle K. Presumed consent: an international comparison and possibilities for change in the United States. Camb Q Healthc Ethics 14 1 (2005) 113-118
138. Lietz K., and Miller L.W. Left ventricular assist devices: evolving devices and indications for use in ischemic heart disease. Curr Opin Cardiol 19 6 (2004) 613-618
139. Chen J.M., Russo M.J., Hammond K.M., et al. Alternate waiting list strategies for heart transplantation maximize donor organ utilization. Ann Thorac Surg 80 1 (2005) 224-228